AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18283141 — intervention group
Group type: COMPARATOR
Intervention: Standard information sheet (group S)
Number of subjects: 100
Study 16449518 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 150
Study 16449518 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 150
Study 16449518 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline
Number of subjects: 150
Study 14739493 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine-needle nonaspiration (FNNA) technique
Number of subjects: 200
Study 14739493 — intervention group
Group type: COMPARATOR
Intervention: Fine-needle aspiration (FNA) technique
Number of subjects: 200
Study 10832669 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin (Rb) 1200 mg/day
Number of subjects: 60
Study 10832669 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 60
Study 9334613 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower energy transurethral microwave thermotherapy (Prostasoft 2.0)
Number of subjects: 50
Study 9334613 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 50
Study 30362389 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene‐Eden‐VIR/Novirin
Number of subjects: 68
Study 30362389 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir and Valacyclovir
Number of subjects: 68
Study 27287818 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized perioperative behavioral/pelvic floor exercise intervention plus midurethral sling
Number of subjects: 433
Study 27287818 — intervention group
Group type: COMPARATOR
Intervention: Midurethral sling alone
Number of subjects: 433
Study 24977293 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual ketamine wafer (25 mg)
Number of subjects: 8
Study 24977293 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ketamine (10 mg)
Number of subjects: 8
Study 22731800 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam and 25 mg of meperidine
Number of subjects: 120
Study 22731800 — intervention group
Group type: COMPARATOR
Intervention: Midazolam and 20 mg of hyoscine N‐butylbromide
Number of subjects: 120
Study 19860965 — intervention group
Group type: EXPERIMENTAL
Intervention: Day Program activities
Number of subjects: 132
Study 16513605 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) after 4 months
Number of subjects: 29
Study 16513605 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) after 13 months
Number of subjects: 29
Study 16513605 — intervention group
Group type: COMPARATOR
Intervention: Mild heart failure without LBBB (Control group)
Number of subjects: 29
Study 16296257 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitening toothpaste containing Perlite
Number of subjects: 20
Study 16296257 — intervention group
Group type: COMPARATOR
Intervention: Standard silica toothpaste
Number of subjects: 20
Study 11737007 — intervention group
Group type: EXPERIMENTAL
Intervention: OPFA 6 g a day for 16 weeks
Number of subjects: 196
Study 11737007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 9148018 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine + Immunoglobulin (4 ml given simultaneously with the first vaccine injection)
Number of subjects: 80
Study 9148018 — intervention group
Group type: COMPARATOR
Intervention: Vaccine alone
Number of subjects: 80
Study 8424426 — intervention group
Group type: EXPERIMENTAL
Intervention: Total enteral nutrition
Number of subjects: 42
Study 8424426 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition
Number of subjects: 42
Study 3118589 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg acemetacin t.i.d. for 1 week
Number of subjects: 20
Study 3118589 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 1 week
Number of subjects: 20
Study 3118589 — intervention group
Group type: EXPERIMENTAL
Intervention: Acemetacin
Number of subjects: 20
Study 3118589 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 20
Study 28522745 — intervention group
Group type: EXPERIMENTAL
Intervention: 27 tailored cessation emails (deluxe email group (DEG))
Number of subjects: 1070
Study 28522745 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 to 4 tailored emails with links to downloadable booklets (basic email group (BEG))
Number of subjects: 1070
Study 28522745 — intervention group
Group type: COMPARATOR
Intervention: Single non‐tailored email (single email group (SEG))
Number of subjects: 1070
Study 28522745 — intervention group
Group type: COMPARATOR
Intervention: DEG compared to SEG
Number of subjects: 1070
Study 28522745 — intervention group
Group type: COMPARATOR
Intervention: BEG compared to SEG
Number of subjects: 1070
Study 28522745 — intervention group
Group type: COMPARATOR
Intervention: DEG compared to SEG for use of non‐medication aids
Number of subjects: 1070
Study 29233854 — intervention group
Group type: EXPERIMENTAL
Intervention: Adventure video game (Night Shift)
Number of subjects: 368
Study 29233854 — intervention group
Group type: COMPARATOR
Intervention: Traditional educational apps (myATLS and Trauma Life Support MCQ Review)
Number of subjects: 368
Study 25315663 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg every 4 weeks (n=91)
Number of subjects: 183
Study 25315663 — intervention group
Group type: COMPARATOR
Intervention: Grid laser photocoagulation (n=92)
Number of subjects: 183
Study 23745991 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (2.0 grams orally three times per day, 6.0 grams daily)
Number of subjects: 30
Study 23745991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 20734445 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 1538
Study 19015067 — intervention group
Group type: EXPERIMENTAL
Intervention: New technologies in oncological surgery
Number of subjects: 0
Study 16961681 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 44
Study 16961681 — intervention group
Group type: COMPARATOR
Intervention: Monitoring group
Number of subjects: 44
Study 14515012 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management intervention
Number of subjects: 16
Study 14515012 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 16
Study 11046212 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-control PTV at 4 cm H2O
Number of subjects: 7
Study 11046212 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-control PTV at 0 cm H2O
Number of subjects: 7
Study 11046212 — intervention group
Group type: EXPERIMENTAL
Intervention: After extubation
Number of subjects: 7
Study 11046212 — intervention group
Group type: COMPARATOR
Intervention: Pressure-control PTV at 16 cm H2O
Number of subjects: 7
Study 11046212 — intervention group
Group type: COMPARATOR
Intervention: Pressure-control PTV at 12 cm H2O
Number of subjects: 7
Study 11046212 — intervention group
Group type: COMPARATOR
Intervention: Pressure-control PTV at 8 cm H2O
Number of subjects: 7
Study 9550777 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted full intensity oral anticoagulation (target range: 3.0-4.0 INR)
Number of subjects: 8700
Study 9550777 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose aspirin
Number of subjects: 8700
Study 9550777 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of low dose aspirin and adjusted low intensity oral anticoagulation (target range: 2.0-2.5 INR)
Number of subjects: 8700
Study 8406632 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfilariae of Wuchereria bancrofti
Number of subjects: 2141
Study 8406632 — intervention group
Group type: EXPERIMENTAL
Intervention: Filarial disease
Number of subjects: 2141
Study 8406632 — intervention group
Group type: EXPERIMENTAL
Intervention: Filarial endemicity
Number of subjects: 2141
Study 8406632 — intervention group
Group type: EXPERIMENTAL
Intervention: Culex quinquefasciatus as the vector
Number of subjects: 2141
Study 3530075 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 106
Study 3530075 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin/Tobramycin
Number of subjects: 106
Study 30982349 — intervention group
Group type: EXPERIMENTAL
Intervention: Selexipag
Number of subjects: 0
Study 30982349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28067891 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive web-based intervention including My Healthy Heart Profile, tailored calorie-restricted diet, and interactive prevention program.
Number of subjects: 160
Study 28067891 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving general information about cardiovascular diseases and MetS risk factors via the website.
Number of subjects: 160
Study 25465185 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary tumour resection
Number of subjects: 810
Study 25465185 — intervention group
Group type: COMPARATOR
Intervention: Non-resection group
Number of subjects: 810
Study 23425152 — intervention group
Group type: EXPERIMENTAL
Intervention: OSFE with deproteinized bovine bone mineral (DBBM) mixed with autogenous bone chips (Group1)
Number of subjects: 45
Study 23425152 — intervention group
Group type: COMPARATOR
Intervention: OSFE without grafting (Group2)
Number of subjects: 45
Study 21500879 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmtop computer-delivered treatment (CDT) for smoking relapse prevention for one additional month
Number of subjects: 302
Study 21500879 — intervention group
Group type: COMPARATOR
Intervention: No further computer-delivered treatment or assessment (EMA-Only)
Number of subjects: 302
Study 18274742 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI assessment of bone marrow edema (BME)
Number of subjects: 19
Study 18274742 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI values
Number of subjects: 19
Study 18274742 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathology
Number of subjects: 19
Study 16685521 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management interventions (education, reassurance, lifestyle modification, behavioral changes)
Number of subjects: 0
Study 14691684 — intervention group
Group type: EXPERIMENTAL
Intervention: Active absorbable algal calcium (AAA Ca) 900 mg/day
Number of subjects: 0
Study 14691684 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (CaCO(3))
Number of subjects: 0
Study 14691684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11240873 — intervention group
Group type: EXPERIMENTAL
Intervention: Peribulbar block
Number of subjects: 50
Study 11240873 — intervention group
Group type: COMPARATOR
Intervention: Intravenous pethidine (control group)
Number of subjects: 50
Study 9250797 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis C virus (HCV) infection
Number of subjects: 110
Study 8318243 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.3 mg
Number of subjects: 24
Study 8318243 — intervention group
Group type: COMPARATOR
Intervention: Intravenous clonidine 0.3 micrograms/kg/hr and fentanyl 25 micrograms/kg
Number of subjects: 24
Study 2948466 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate roentgenograms
Number of subjects: 101
Study 2948466 — intervention group
Group type: COMPARATOR
Intervention: Brief educational intervention with roentgenography only for failure to improve
Number of subjects: 101
Study 2948466 — intervention group
Group type: COMPARATOR
Intervention: Brief educational intervention
Number of subjects: 101
Study 2948466 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (roentgenography and education)
Number of subjects: 101
Study 30518511 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg) daily until the morning of colonoscopy
Number of subjects: 387
Study 30518511 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily until the morning of colonoscopy
Number of subjects: 387
Study 28500214 — intervention group
Group type: EXPERIMENTAL
Intervention: TeLiPro (telemedical coaching, formula diet, self-monitored blood glucose for 12 weeks)
Number of subjects: 202
Study 28500214 — intervention group
Group type: COMPARATOR
Intervention: Control (weighing scales and step counters, routine care)
Number of subjects: 202
Study 28500214 — intervention group
Group type: EXPERIMENTAL
Intervention: TeLiPro
Number of subjects: 202
Study 28500214 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 202
Study 26030041 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 watts RFA energy
Number of subjects: 60
Study 26030041 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 watts RFA energy
Number of subjects: 60
Study 23290991 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 20
Study 23290991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21355967 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg/day
Number of subjects: 665
Study 21355967 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg/day
Number of subjects: 665
Study 21355967 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 100 mg/day
Number of subjects: 665
Study 19433391 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpegylated liposomal doxorubicin (NLD) 60 mg/m2 every 3 weeks and trastuzumab loading dose 4 mg/kg followed by 2 mg/kg weekly
Number of subjects: 40
Study 19433391 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpegylated liposomal doxorubicin (NLD) plus trastuzumab
Number of subjects: 40
Study 17024639 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemopure (30 g)
Number of subjects: 12
Study 17024639 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemopure (45 g)
Number of subjects: 12
Study 17024639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15564161 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary ileostomy
Number of subjects: 0
Study 15564161 — intervention group
Group type: COMPARATOR
Intervention: Temporary colostomy
Number of subjects: 0
Study 11393099 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation program (MRP) including physical therapy, nurse-supervised exercise, and discharge planning
Number of subjects: 155
Study 11393099 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation program (MRP)
Number of subjects: 155
Study 11393099 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 155
Study 9514231 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic percutaneous transluminal angioplasty (PTA)
Number of subjects: 120
Study 9514231 — intervention group
Group type: COMPARATOR
Intervention: No intervention (observation)
Number of subjects: 120
Study 8065724 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoretically applied dexamethasone in a lidocaine vehicle
Number of subjects: 53
Study 8065724 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 53
Study 2568261 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg bisoprolol
Number of subjects: 25
Study 2568261 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg bisoprolol
Number of subjects: 25
Study 4948417 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral streptomycin-dependent mutant Shigella vaccines
Number of subjects: 0
Study 31124836 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfaxalone (0.5 mg/kg bolus intravenous injection)
Number of subjects: 12
Study 29777241 — intervention group
Group type: EXPERIMENTAL
Intervention: Chickpeas (GI=28, GL=14, 50g available carbohydrates)
Number of subjects: 17
Study 29777241 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycemic load meals
Number of subjects: 17
Study 29777241 — intervention group
Group type: COMPARATOR
Intervention: Large potato (GI=85, GL=42, 50g carbohydrates)
Number of subjects: 17
Study 29777241 — intervention group
Group type: COMPARATOR
Intervention: Pasta (GI=45, GL=42, 94g carbohydrates)
Number of subjects: 17
Study 28814323 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarolaner (Simparic™) at 2 mg/kg
Number of subjects: 20
Study 28814323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 25665908 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth-borne rapid maxillary expansion (hyrax)
Number of subjects: 61
Study 25665908 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-borne rapid maxillary expansion (miniscrew-implant-based)
Number of subjects: 61
Study 25665908 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study 23968698 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymer biolimus-eluting stents (BES) (n = 857)
Number of subjects: 1707
Study 23968698 — intervention group
Group type: COMPARATOR
Intervention: Durable polymer sirolimus-eluting stents (SES) (n = 850)
Number of subjects: 1707
Study 21348211 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 IU of oxytocin followed by an infusion of 2.5 IU x h(‐1)
Number of subjects: 104
Study 21348211 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of 20 IU at a rate of 700 mlU x min(‐1) followed by 10 IU x min(‐1)
Number of subjects: 104
Study 19485969 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (900 mg tapering to 600 mg or 1200 mg tapering to 800 mg)
Number of subjects: 100
Study 19485969 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam (6 mg tapering to 4 mg)
Number of subjects: 100
Study 16815858 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 1.5 mg/day
Number of subjects: 634
Study 16815858 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 3.0 mg/day
Number of subjects: 634
Study 16815858 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 634
Study 12760978 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg x2)
Number of subjects: 300
Study 11129502 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil therapy starting with 0.8 mg/kg/4 days, increased by 0.1 mg/kg/4 days cycle
Number of subjects: 11
Study 11129502 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil therapy
Number of subjects: 11
Study 9329225 — intervention group
Group type: EXPERIMENTAL
Intervention: Pen-based computer technology for H/C-PRI assessments
Number of subjects: 476
Study 9329225 — intervention group
Group type: COMPARATOR
Intervention: Usual documentation method for H/C-PRI assessments
Number of subjects: 476
Study 8448714 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 44
Study 8448714 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 44
Study 8448714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 2578971 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of half doses of terbutaline (5 mg twice daily) and theophylline (250 mg twice daily)
Number of subjects: 31
Study 2578971 — intervention group
Group type: COMPARATOR
Intervention: Theophylline alone (500 mg twice daily)
Number of subjects: 31
Study 2578971 — intervention group
Group type: COMPARATOR
Intervention: High-dose combination treatment (theophylline 500 mg twice daily and terbutaline 10 mg twice daily)
Number of subjects: 31
Study 2578971 — intervention group
Group type: COMPARATOR
Intervention: High-dose combination treatment
Number of subjects: 31
Study 30816772 — intervention group
Group type: EXPERIMENTAL
Intervention: Worldview-support condition
Number of subjects: 398
Study 30816772 — intervention group
Group type: COMPARATOR
Intervention: Worldview-threat condition
Number of subjects: 398
Study 30012046 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold/Liquid Diet
Number of subjects: 194
Study 30012046 — intervention group
Group type: COMPARATOR
Intervention: Regular Diet
Number of subjects: 194
Study 26196199 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition (EN) with medium-chain triglyceride (MCT) formula
Number of subjects: 15
Study 26196199 — intervention group
Group type: COMPARATOR
Intervention: Oral nutrition (PO) with medium-chain triglyceride (MCT) formula
Number of subjects: 15
Study 24708781 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE II score-based model
Number of subjects: 1625
Study 24708781 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPS II score-based model
Number of subjects: 1625
Study 24708781 — intervention group
Group type: EXPERIMENTAL
Intervention: SOFA score-based model
Number of subjects: 1625
Study 24708781 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted SOFA-based model (including age and GCS)
Number of subjects: 1625
Study 24708781 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference model (age and GCS)
Number of subjects: 1625
Study 21763445 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Enterococcus faecium IS-27526
Number of subjects: 0
Study 21763445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16142595 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg daily
Number of subjects: 23
Study 16142595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 11196013 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient prism lenses
Number of subjects: 24
Study 9462610 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise electrocardiography (ECG)
Number of subjects: 407
Study 9462610 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography (DSE)
Number of subjects: 407
Study 7532475 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506/prednisone
Number of subjects: 204
Study 7532475 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506/azathioprine/prednisone
Number of subjects: 204
Study 7532475 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly named)
Number of subjects: 204
Study 2572477 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl-midazolam-flumazenil
Number of subjects: 50
Study 2572477 — intervention group
Group type: COMPARATOR
Intervention: Pethidine-diazepam-ketamine
Number of subjects: 50
Study 799984 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam 60 mg
Number of subjects: 125
Study 799984 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 600 mg
Number of subjects: 125
Study 799984 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam 30 mg
Number of subjects: 125
Study 799984 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 300 mg
Number of subjects: 125